期刊文献+

5-硝基吲唑衍生物对HeLa细胞的放射增敏作用

Radiosensitization of nitroindazole derivatives on HeLa cells
原文传递
导出
摘要 目的研究5-硝基吲唑-3-甲酰亚氨基二乙酸的细胞毒性,以及对HeLa细胞的放射增敏作用。方法取指数生长期的HeLa细胞,接种于96孔板,加入不同浓度的药物作用后,用噻唑蓝比色法(MTT法)测定存活分数,并比较不同药物剂量加照射的实验组与单纯照射组的细胞存活分数。结果5-硝基吲唑-3-甲酰亚氨基二乙酸对HeLa细胞的毒性较小。该药物对HeLa细胞有放射增敏作用,且乏氧处理的效果优于有氧处理:0、6、12、24、48、96μg/ml药物乏氧处理,存活率分别为0.91、0.87、0.84、0.81、0.76、0.60;48、96μg/ml药物有氧处理,存活率分别为0.85和0.73。结论5-硝基吲唑-3-甲酰亚氨基二乙酸对HeLa细胞的毒性较小,且具有一定的乏氧放射增敏剂特征。 Objective To investigate the cytotoxicity and radiosensitization of 5-nitroindazole-3- formyliminodiacetic acid on HeLa ceils. Methods HeLa cells in exponential growth phase were incubated in culture media with different doses and the survival rate was determined by MTT assay. The survival rate of cells receiving radiation combined with different doses of medicine was compared with that of the control. Results The cytotoxicity of 5-nitroindazole-3-formyliminodiacetic acid on HeLa ceils was very low. The drug had hypoxia radiosensitizing effect on HeLa cells. At doses of 0, 6, 12, 24, 48 and 96 μg/ml under hypoxia ,the survival rate were 0.91, 0.87, 0. 84, 0. 81,0.76 and 0. 60, respectively. At the dosage of 48 and 96 μg/ml,the survival rate were 0.85 and 0.73 under oxygenous). Conclusions 5-Nitroindazole- 3-formyliminodiacetic acid has low cytotoxicity and rediosensitizing effect on HeLa ceils.
出处 《中华放射医学与防护杂志》 CAS CSCD 北大核心 2010年第1期20-21,共2页 Chinese Journal of Radiological Medicine and Protection
基金 天津市自然科学基金(08JCYBJC07400)
关键词 5-硝基吲唑-3-甲酰亚氨基二乙酸 HELA细胞 乏氧 放射增敏 5-Nitroindazole-3-formyliminodiacetic acid HeLa cells Hypoxia Radiosensitization
  • 相关文献

参考文献5

二级参考文献13

  • 1Jian-GangJiang,Jiang-BoTang,Chun-LianChen,Bao-XingLiut,Xiang-NingFu,Zhi-HuiZhu,WeiQu,KatherineCianflone,MichaelP.Waalkes,Dao-WenWang.Expression of cyclooxygenase-2 in human esophageal squamous cell carcinomas[J].World Journal of Gastroenterology,2004,10(15):2168-2173. 被引量:12
  • 2Hemandez-Vargas H, Palacios J, Moreno-Bueno G. Telling cells how to die: docetaxel therapy in cancer cell lines[J]. Ceil Cycle, 2007, 6(7) :780 -783.
  • 3Roja G. , Roo PS. Anticancer compounds from tissue cultures of medicinal plants [ J ]. Journal of Herbs, Spicies & Medicinal Plants, 2000, 7(2):71 -102.
  • 4Park Y, Kim B, Ryoo B, et al. A phase Ⅱ study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with ad-vanced gastric cancer [ J ]. Br J Cancer, 2006, 94 ( 7 ) : 959 - 963.
  • 5Engels FK, Mathot RA, Verweij J. Ahernative drug formulations of docetaxel : a review [ J]. Anticancer Drugs, 2007, 18 (2) :95 - 103.
  • 6Ramaswamy B, Puhalla S. Docetaxel: a tubulin-stabilizing agent approved for the management of several solid tumors[J]. Drags Today (Barc) , 2006, 42(4):265-279.
  • 7Bergqvist M, Brattstrom D, Gullbo J, et al. p53 status and its in vitro relationship with radiosensitivity and chemosensitivity in lung cancer[J]. Anticancer Res, 2003,23(2B) : 1207 - 1212.
  • 8Nikiforova MN, Stringer JR, Blough R, el al. Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells[J]. Science, 2000, 290(5489) :138 -141.
  • 9Baker SD, Sparreboom A, Verweij J. Clinical pharmacokinetics of docetaxel: recent developments [ J ]. Clin Pharmacokinet, 2006, 45(3) :235 -252.
  • 10Engels FK, Sparreboom A, Mathot RA, et al. Potential for improvement of docetaxel-based chemotherapy: a pharmacological review[ J ]. Br J Cancer, 2005, 93 (2) : 173 - 177.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部